Impact Factor : 0.548
*Corresponding author:Georgios Mikellides, Honorary Assistant Professor University of Nicosia, Consultant Psychiatrist at Cyprus rTMS
Received: August 08, 2018; Published: August 14, 2018
To view the Full Article Peer-reviewed Article PDF
The use of repetitive transcranial magnetic stimulation has grown over the last ten years since the FDA approval in 2008 and has been also included in NICE UK as an optional treatment  and it is likely to continue to grow in terms of its use as it has been showing the following promising findings: good results in a variety of neuropsychiatric disorders such as anxiety , obsessive compulsive disorder , auditory hallucinations , PTSD , tinnitus , migraine , post-stroke rehabilitation  etc. It also provides a neuroprotective mechanism  which may enhance cognitive function.
Introduction | A Case Study | Conclusion | References |